NASDAQ: TNXP
Tonix Pharmaceuticals Holding Corp.CIK 0001430306 · Pharmaceutical Preparations
Each report below shows a 3-bullet preview. Free accounts read 3 full reports a month — narrative summary, section diffs, and EDGAR-cited quotes.
Sign up freeWant to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.
Summary not yet generated.
Tonix secures GPO agreement expanding TONMYA coverage to 17M commercially insured patients
2 material changes detected. Sign up free to read the summary.
Partner
Trade TNXP commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Tonix publishes Phase 1 results showing TNX-1500 blocked immune responses at all doses
3 material changes detected. Sign up free to read the summary.
Tonix presents Phase 1 data for Lyme disease candidate TNX-4800, targets Phase 2 trial in H1 2027
3 material changes detected. Sign up free to read the summary.
Tonix launches first product TONMYA, revenue triples to $6.9M but losses widen to $40M
5 material changes detected. Sign up free to read the summary.
Tonix Pharmaceuticals reports Q1 2026 operating results
2 material changes detected. Sign up free to read the summary.
Tonix shareholders authorize reverse stock split up to 1-for-250, approve equity plan
3 material changes detected. Sign up free to read the summary.
Tonix launches first approved drug TONMYA, expands pipeline with Lyme prevention asset
5 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.